Compound profile
Also known as: Thymosin Beta-4 fragment · Tβ4
A synthetic peptide associated with thymosin beta-4 research, commonly discussed alongside soft-tissue recovery and mobility. Often paired conversationally with BPC-157.
TB-500 is the name most often used online for a research peptide connected to thymosin beta-4 (Tβ4), a small protein that occurs naturally in nearly every cell in the body and in particularly high concentrations in platelets and wound fluid. Tβ4 itself was first isolated from bovine thymus tissue by Allan Goldstein and colleagues in the 1960s as part of a broader research program into thymus-derived peptides, and later work through the 1980s and 1990s, including contributions from Hynda Kleinman's group, established its role in cell movement and wound healing in animal models.
The name "TB-500" is not a formal pharmacological designation, and that is a real source of confusion in this space. Native Tβ4 is 43 amino acids long, but products sold under the TB-500 label have varied in what they actually contain, sometimes the full-length sequence, sometimes a much shorter fragment built around the actin-binding motif that is thought to carry much of Tβ4's biological activity. Anyone researching TB-500 should understand that the name alone does not guarantee a consistent compound.
A separate company, RegeneRx, developed a full-length synthetic Tβ4 under the code RGN-352 and has tested it in early-phase human trials for other indications, including certain skin and eye conditions. That work represents some of the only real human data connected to this peptide family, and it does not map directly onto the informal recovery and injury use that TB-500 is discussed for in fitness and biohacking communities, where the underlying evidence is overwhelmingly preclinical and where TB-500 is frequently paired conversationally with BPC-157.
Thymosin beta-4 is involved in actin regulation and cell migration. TB-500 is marketed as related research material; mapping commercial peptides to endogenous Tβ4 biology requires careful reading of primary sources.
The core biological role researchers describe for thymosin beta-4 is as a G-actin sequestering protein, meaning it binds up the building-block form of actin, a structural protein involved in nearly every process that requires a cell to change shape or move. By regulating how much free actin is available, Tβ4 influences cell migration, which is central to its proposed role in tissue repair: it is thought to help endothelial cells, keratinocytes, and various progenitor cells travel to injury sites and organize new tissue.
Animal studies describe additional downstream effects tied to this actin regulation, including promotion of new blood vessel formation (angiogenesis), reduced inflammation, and in some cardiac injury models, improved migration of cardiac progenitor cells and reduced scar tissue formation after induced heart attacks in rodents. Separate preclinical work has looked at effects on hair follicle stem cells and corneal repair. Almost all of this mechanistic picture comes from cell culture and animal research rather than confirmed human pharmacology, and given the naming inconsistencies described above, it is not always clear which specific molecule a given study is even testing.
Thymosin beta-4 literature includes preclinical healing and cardiac repair models. Direct, high-quality human athletic injury trials for TB-500 specifically are sparse.
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Animal studies report accelerated healing of skin wounds and improved tissue repair, an effect researchers link back to Tβ4's role in cell migration and actin regulation.
Rodent models of induced heart attack report improved cardiac progenitor cell migration and reduced scar formation with Tβ4 administration.
Preclinical work describes increased blood vessel formation at injury sites, a proposed contributor to faster tissue repair across multiple animal injury models.
Animal and cell studies report reduced markers of inflammation alongside the reparative effects described above.
Nomenclature confusion between TB-500 and full-length Tβ4 is common. Human dosing literature for athletes is weak. Regulatory status of research peptides differs by jurisdiction.
The biggest practical issue with TB-500 is identity, not just evidence quality. Because the name is a marketing term rather than a regulated designation, there is no guarantee that a given vial contains full-length thymosin beta-4, a fragment of it, or something else entirely, and independent testing of research-chemical products in this space has documented exactly that kind of inconsistency. That uncertainty sits on top of an evidence base that is almost entirely preclinical, animal and cell studies of wound healing, cardiac repair, and angiogenesis, with very little in the way of controlled human trials for the athletic injury and recovery use it's discussed for online. The early-phase human trials that do exist, run by RegeneRx using its own full-length synthetic Tβ4 (RGN-352) for unrelated indications like dry eye and epidermolysis bullosa, do not validate the informal recovery protocols circulating in fitness communities, and they were conducted with a specific, verified compound rather than whatever happens to be sold as TB-500. As with other unregulated research peptides, TB-500 is not FDA approved for any use, and anyone considering it is relying on unregulated manufacturing with no long-term human safety data specific to the product as typically sold.
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
Commonly discussed together
Online communities often discuss GHK-Cu, BPC-157, and TB-500 together under the informal name “GLOW,” usually in the context of skin quality and soft-tissue recovery conversations, not as a single studied product.
GLOW is a community nickname, not a validated clinical protocol. There are no dose schedules here. Read each peptide’s evidence level and primary sources separately.
Skin / repair · Recovery
Commonly discussed together
BPC-157 and TB-500 are frequently mentioned side-by-side in recovery forums as a “commonly discussed together” pairing for soft-tissue talk, again as folklore adjacency, not a packaged regimen.
Preclinical literature for each compound does not equal a combined human protocol. No timelines or doses are provided on STACKD Research.
Recovery
